BR0308904A - Método de tratamento de gastroparesia, e, uso de um composto de glp-1 - Google Patents

Método de tratamento de gastroparesia, e, uso de um composto de glp-1

Info

Publication number
BR0308904A
BR0308904A BR0308904-5A BR0308904A BR0308904A BR 0308904 A BR0308904 A BR 0308904A BR 0308904 A BR0308904 A BR 0308904A BR 0308904 A BR0308904 A BR 0308904A
Authority
BR
Brazil
Prior art keywords
glp
gastroparesis
treatment
compound
compounds
Prior art date
Application number
BR0308904-5A
Other languages
English (en)
Inventor
Joseph Anthony Jakubowski
Thurman Dwight Mckinney
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0308904A publication Critical patent/BR0308904A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MéTODO DE TRATAMENTO DE GASTROPARESIA, E, USO DE UM COMPOSTO DE GLP- 1". A invenção refere-se ao uso de compostos de GLP-1 para o tratamento de gastroparesia. Paciente com gastroparesia em geral experimenta um retardamento no esvaziamento gástrico. Compostos de GLP-1 podem ser utilizados para o esvaziamento gástrico nestes pacientes.
BR0308904-5A 2002-04-10 2003-03-27 Método de tratamento de gastroparesia, e, uso de um composto de glp-1 BR0308904A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37165002P 2002-04-10 2002-04-10
PCT/US2003/008457 WO2003087139A2 (en) 2002-04-10 2003-03-27 Treatment of gastroparesis

Publications (1)

Publication Number Publication Date
BR0308904A true BR0308904A (pt) 2005-05-03

Family

ID=29250714

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308904-5A BR0308904A (pt) 2002-04-10 2003-03-27 Método de tratamento de gastroparesia, e, uso de um composto de glp-1

Country Status (18)

Country Link
US (1) US20050164925A1 (pt)
EP (1) EP1496924A4 (pt)
JP (1) JP2005530732A (pt)
KR (1) KR20040098063A (pt)
CN (1) CN1735423A (pt)
AU (1) AU2003220403A1 (pt)
BR (1) BR0308904A (pt)
CA (1) CA2480858A1 (pt)
EA (1) EA200401345A1 (pt)
EC (1) ECSP045345A (pt)
HR (1) HRP20040939A2 (pt)
IL (1) IL164266A0 (pt)
MX (1) MXPA04009929A (pt)
NO (1) NO20044815L (pt)
NZ (1) NZ535684A (pt)
PL (1) PL373658A1 (pt)
WO (1) WO2003087139A2 (pt)
ZA (1) ZA200408111B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US8792985B2 (en) 2003-07-21 2014-07-29 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
TW200522976A (en) * 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
EP1670515A2 (en) * 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1793891B1 (en) 2004-08-18 2011-11-09 Metacure Limited Monitoring, analysis, and regulation of eating habits
US9821158B2 (en) 2005-02-17 2017-11-21 Metacure Limited Non-immediate effects of therapy
US9339190B2 (en) 2005-02-17 2016-05-17 Metacure Limited Charger with data transfer capabilities
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
KR20070120112A (ko) 2005-03-18 2007-12-21 노보 노르디스크 에이/에스 연장형 ｇｌｐ-1 화합물
WO2006129321A2 (en) 2005-06-02 2006-12-07 Metacure N.V. Gi lead implantation
US8463404B2 (en) 2005-03-24 2013-06-11 Metacure Limited Electrode assemblies, tools, and methods for gastric wall implantation
WO2006102626A2 (en) * 2005-03-24 2006-09-28 Metacure Nv Wireless leads for gastrointestinal tract applications
US8442841B2 (en) * 2005-10-20 2013-05-14 Matacure N.V. Patient selection method for assisting weight loss
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
AU2012203915B9 (en) * 2006-04-20 2014-10-09 Amgen Inc. GLP-1 compounds
EP2574624A1 (en) * 2006-04-20 2013-04-03 Amgen Inc. GLP-1 compounds
WO2008139463A2 (en) * 2007-05-09 2008-11-20 Metacure Ltd. Analysis and regulation of food intake
US8423130B2 (en) * 2008-05-09 2013-04-16 Metacure Limited Optimization of thresholds for eating detection
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
EP2482840A4 (en) * 2009-08-07 2013-06-26 Mannkind Corp VAL (8) GLP-1 COMPOSITION AND METHOD FOR THE TREATMENT OF REAGENTS AND / OR IRRITATION SYNDROME
EP2525834B1 (en) 2010-01-22 2019-07-17 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
US20130123460A1 (en) 2010-04-30 2013-05-16 Sanwa Kagaku Kenkyusho Co., Ltd. Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014096150A1 (en) 2012-12-21 2014-06-26 Sanofi Dual glp1/gip or trigonal glp1/gip/glucagon agonists
EP2981282B1 (en) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand

Also Published As

Publication number Publication date
CA2480858A1 (en) 2003-10-23
CN1735423A (zh) 2006-02-15
NZ535684A (en) 2006-03-31
US20050164925A1 (en) 2005-07-28
MXPA04009929A (es) 2006-03-10
PL373658A1 (en) 2005-09-05
NO20044815L (no) 2005-01-07
EA200401345A1 (ru) 2005-08-25
EP1496924A2 (en) 2005-01-19
ECSP045345A (es) 2006-04-19
ZA200408111B (en) 2005-10-07
HRP20040939A2 (en) 2004-12-31
WO2003087139A3 (en) 2004-01-08
JP2005530732A (ja) 2005-10-13
WO2003087139A2 (en) 2003-10-23
EP1496924A4 (en) 2007-05-30
AU2003220403A1 (en) 2003-10-27
KR20040098063A (ko) 2004-11-18
IL164266A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
MXPA03003870A (es) Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes.
WO2003009838A1 (fr) Utilisation de composes de stilbene dans la preparation de medicaments pour le traitement ou la prevention du diabete et des maladies associees au retrovirus
MXPA04001525A (es) Analogos de peptido -1 similar al glucagon.
IL194950A0 (en) Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
DE60026704D1 (de) (S,S)-Reboxetine zur Behandlung chronischer Schmerzen
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
GB0225474D0 (en) Therapeutic agents
WO2002096363A3 (en) Method for treating fibrotic diseases or other indications
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
AU2000276362A1 (en) Composition for the treatment of diabetes
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
GB9907571D0 (en) Compounds
SE0004101D0 (sv) New use
AU4937699A (en) Use of succinic acid or salts thereof for the treatment of diabetes mellitus andwound healing
NZ504124A (en) Phenyl-alkyl-imidazoles and use in treating inflammatory disease
WO2002072098A8 (en) Method of treatment
BR0316059A (pt) Uso de fosinopril para reduzir eventos cardiovasculares em pacientes de diálise

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A,4A, 5A,6A E 7A ANUIDADES

B08J Incorrect entry in the gazette republished [chapter 8.10 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2051 DE 27/04/2010. TEXTO CORRETO: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.10 DA RPI 2068 DE 24/08/2010.